Vasa Therapeutics Advances Heart Failure Treatment with IND Approval
Phase 1c Clinical Trial to Begin Immediately
Vasa Therapeutics, a private clinical-stage biotechnology company focused on cardiovascular and metabolic aging, has achieved an important milestone by receiving clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for VS-041. This innovative small molecule inhibitor targets matrix metalloproteinases and will enter a Phase 1c clinical trial to help individuals suffering from Heart Failure with Preserved Ejection Fraction (HFpEF).
"Following a successful Phase 1 trial with healthy volunteers earlier this year, we are thrilled to begin this Phase 1c study for VS-041 on participants diagnosed with HFpEF alongside elevated serum levels of endotrophin. This IND clearance signifies a substantial achievement for Vasa, showcasing the robustness of our scientific approach and development plan," stated Artur Plonowski, MD, Chief Executive Officer of Vasa Therapeutics. "Through this study, we aim to investigate vital effects of VS-041 on clinical and prognostic biomarkers of HFpEF, particularly focusing on endotrophin, a contributor to increased morbidity and mortality rates."
The Phase 1c study will explore the safety and tolerability of VS-041 in participants with HFpEF and heightened serum endotrophin levels. Insights gained from this trial may validate target engagement and assist in selecting dosing parameters for further developmental phases.
Renowned cardiologist Dr. Julio Chirinos, an expert in HFpEF and endotrophin and a professor at the Perelman School of Medicine at the University of Pennsylvania, emphasized, "Endotrophin serves as a significant forecaster of outcomes in HFpEF and may play a critical role in its underlying pathology. This Phase 1c study of VS-041 will represent an essential progression in assessing the therapeutic potential of inhibiting endotrophin production."
About VS-041
VS-041 is an oral medication developed by Vasa, targeting HFpEF and chronic diseases highlighted by fibroinflammation, such as hypertrophic cardiomyopathy and chronic kidney disease. Preclinical studies on HFpEF models have demonstrated that VS-041 effectively diminishes cardiac fibrosis and enhances diastolic heart function. Additionally, this compound inhibits the ex-vivo release of endotrophin from primary human cardiac fibroblasts. Funding for VS-041's development was partially provided by the European Regional Development Fund and the Polish National Centre for Research and Development.
About Heart Failure with Preserved Ejection Fraction (HFpEF)
HFpEF is a multifaceted and progressive heart failure variation, marked by stiffening and fibroinflammation of the cardiac muscle along with impaired relaxation while maintaining normal contractile functions. In the U.S. alone, HFpEF is estimated to affect around three million individuals and approximately ten million worldwide. This condition involves fibroinflammation regulated by matrix metalloproteinases (MMPs). Current treatment options yield some clinical improvements; however, none offer disease modification or enduring benefits following treatment cessation.
The University of Pennsylvania holds patents related to diagnostic approaches utilizing plasma and urine proteins to forecast outcomes for patients suffering from HFpEF.
About Vasa Therapeutics
Vasa Therapeutics operates as a clinical-stage biopharmaceutical entity that designs innovative therapeutics targeting cardiovascular and muscle aging. The company has developed a pipeline consisting of four distinct assets that address pressing medical needs in heart failure, sarcopenia, rare neuromuscular disorders, peripheral arterial disease, and life-threatening arrhythmias.
Apart from their lead program VS-041, Vasa has introduced a collection of long-acting apelin medications aimed at rare neuromuscular diseases, peripheral artery disease (PAD), and sarcopenia. These have shown promising potential in preserving muscle function, boosting cardiac output, and counteracting age-related sarcopenia during preclinical evaluations. Furthermore, Vasa's long-acting apelin, VS-241, is set to begin clinical trials in the near future.
Recognized for its innovations, Vasa recently earned the 2025 TOP10 Longevity Breakthrough Award. Boasting a team of top-tier professionals with an impressive history of successful drug development in both large pharmaceutical firms and small biotech enterprises, Vasa Therapeutics merges dedication and science in every endeavor it undertakes.
Frequently Asked Questions
What is the purpose of the Phase 1c clinical trial for VS-041?
The Phase 1c clinical trial aims to evaluate the safety and tolerability of VS-041 in participants with HFpEF and elevated serum endotrophin levels.
How effective is VS-041 against HFpEF?
VS-041 has shown potential in reducing cardiac fibrosis and significantly enhancing diastolic heart functions in preclinical HFpEF models.
What is the significance of endotrophin in HFpEF treatment?
Endotrophin is a strong predictor of outcomes in HFpEF, and its inhibition may play a crucial role in addressing the condition's pathophysiology.
Who are the key individuals involved in Vasa Therapeutics?
Artur Plonowski, MD, serves as the CEO, and Dr. Julio Chirinos, an expert in HFpEF, plays a crucial role in monitoring the clinical study.
When might VS-241 begin clinical trials?
Vasa's long-acting apelin VS-241 is expected to commence clinical trials in the near future.
